1) Chamberlain MC, Glantz M, Groves MD, Wilson WH:Diagnostic tools for neoplastic meningitis:detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 36:S35-S45, 2009
2) Chamberlain MC:Leptomeningeal metastasis. Curr Opin Oncol 22:627-635, 2010
3) Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM:Leptomeningeal metastases in the MRI era. Neurology 74:1449-1454, 2010
4) Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, Veyret C, Blot E:Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol 95:421-426, 2009
5) DeAngelis LM:Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38:245-252, 1998
6) de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL:Meningeal carcinomatosis in breast cancer:prognostic factors and outcome. J Neurooncol 104:565-572, 2011
7) Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Diéras V:Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183-2187, 2010
8) Glass JP, Melamed M, Chernik NL, Posner JB:Malignant cells in cerebrospinal fluid(CSF):the meaning of a positive CSF cytology. Neurology 29:1369-1375, 1979
9) Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH:Leptomeningeal metastases from breast cancer:intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129:809-817, 2011
10) Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, André C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC:A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113:83-92, 2013
11) Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J:Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 127:841-844, 2011
12) Platini C, Long J, Walter S:Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778-780, 2006
13) Rudnicka H, Niwińska A, Murawska M:Breast cancer leptomeningeal metastasis--the role of multimodality treatment. J Neurooncol 84:57-62, 2007
14) Souchon R, Feyer P, Thomssen C, Fehm T, Diel I, Nitz U, Janni W, Bischoff J, Sauer R:Clinical Recommendations of DEGRO and AGO on Preferred Standard Palliative Radiotherapy of Bone and Cerebral Metastases, Metastatic Spinal Cord Compression, and Leptomeningeal Carcinomatosis in Breast Cancer. Breast Care(Basel)5:401-407, 2010
15) Wasserstrom WR, Glass JP, Posner JB:Diagnosis and treatment of leptomeningeal metastases from solid tumors:experience with 90 patients. Cancer 49:759-772, 1982